These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3243928)

  • 1. Lack of effect of cholestyramine on phenytoin bioavailability.
    Barzaghi N; Monteleone M; Amione C; Lecchini S; Perucca E; Frigo GM
    J Clin Pharmacol; 1988 Dec; 28(12):1112-4. PubMed ID: 3243928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cholestyramine and colestipol on the absorption of phenytoin.
    Callaghan JT; Tsuru M; Holtzman JL; Hunninghake DB
    Eur J Clin Pharmacol; 1983; 24(5):675-8. PubMed ID: 6873150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cholestyramine resin on single dose valproate pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Diskin CJ
    Int J Clin Pharmacol Ther; 1996 May; 34(5):208-11. PubMed ID: 8738857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide.
    Hunninghake DB; King S; LaCroix K
    Int J Clin Pharmacol Ther Toxicol; 1982 Apr; 20(4):151-4. PubMed ID: 7076343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Does cholestyramine impair the bioavailability of prednisolone?].
    Audétat V; Paumgartner G; Bircher J
    Schweiz Med Wochenschr; 1977 Apr; 107(15):527-8. PubMed ID: 854722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of cholestyramine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Frey R; Wetzelsberger N; Lücker PW; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):250-4. PubMed ID: 9208341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Hagan DR; Betagari S; Doshi DH
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):286-9. PubMed ID: 7921528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cholestyramine on digoxin absorption and excretion in man.
    Hall WH; Shappell SD; Doherty JE
    Am J Cardiol; 1977 Feb; 39(2):213-6. PubMed ID: 835478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules.
    Brown DD; Schmid J; Long RA; Hull JH
    J Clin Pharmacol; 1985; 25(5):360-4. PubMed ID: 4031112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of cholestyramine and colestipol on the absorption of diclofenac in man.
    al-Balla SR; el-Sayed YM; al-Meshal MA; Gouda MW
    Int J Clin Pharmacol Ther; 1994 Aug; 32(8):441-5. PubMed ID: 7981930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract.
    Johansson C; Adamsson U; Stierner U; Lindsten T
    Acta Med Scand; 1978; 204(6):509-12. PubMed ID: 735882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant administration of cholestyramine influences the absorption of troglitazone.
    Young MA; Lettis S; Eastmond R
    Br J Clin Pharmacol; 1998 Jan; 45(1):37-40. PubMed ID: 9489592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.
    Gatti G; Bartoli A; Marchiselli R; Michelucci R; Tassinari CA; Pisani F; Zaccara G; Timmings P; Richens A; Perucca E
    Br J Clin Pharmacol; 1993 Dec; 36(6):603-6. PubMed ID: 12959280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced elimination of warfarin during treatment with cholestyramine.
    Jähnchen E; Meinertz T; Gilfrich HJ; Kersting F; Groth U
    Br J Clin Pharmacol; 1978 May; 5(5):437-40. PubMed ID: 656283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of iron deficiency anaemia and its treatment on single dose phenytoin bioavailability.
    Joshi MV; Pohujani SM; Mehta BC; Acharya VN; Kshirsasgar NA
    Eur J Clin Pharmacol; 1993; 45(4):387-8. PubMed ID: 8299676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of hypocholesterolemic interventions on digoxin bioavailability.
    Brown DD; Juhl RP; Warner SL
    Drug Metab Rev; 1979; 9(1):107-17. PubMed ID: 446263
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of cholestyramine and colestipol on the plasma concentrations of propranolol.
    Hibbard DM; Peters JR; Hunninghake DB
    Br J Clin Pharmacol; 1984 Sep; 18(3):337-42. PubMed ID: 6487473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of enteral feedings on phenytoin sodium absorption from capsules.
    Nishimura LY; Armstrong EP; Plezia PM; Iacono RP
    Drug Intell Clin Pharm; 1988 Feb; 22(2):130-3. PubMed ID: 3127188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.
    Busch U; Heinzel G; Narjes H
    Eur J Clin Pharmacol; 1995; 48(3-4):269-72. PubMed ID: 7589053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
    Kosoglou T; Statkevich P; Johnson-Levonas AO; Paolini JF; Bergman AJ; Alton KB
    Clin Pharmacokinet; 2005; 44(5):467-94. PubMed ID: 15871634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.